Stigma, treatment, and health among stimulant users: Life stage as a moderator

Woodhead, Erin L.; Timko, Christine; Han, Xiaotong; Cucciare, Michael A.

doi:10.1016/j.appdev.2018.11.005

Cited by 8 publications

(6 citation statements)

References 69 publications

(83 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Users are often afraid to attend CAPS AD or any health service, fearing they will be labeled as people with mental problems in their communities. This is observed in the literature, which points out that stigma and prejudice can lead people to seek treatment in protected environments, such as clinics and places far from interactions with family and friends (26) .…”

Section: Discussionmentioning

confidence: 91%

Assessment of stigma and prejudice in the organization of care networks for drug users

et al. 2022

View full text Add to dashboard Cite

Objective: To assess stigma and prejudice in the organization of the Psychosocial Care Network for drug users. Methods: this is a qualitative study, developed through Empowerment Assessment. The survey was conducted in a municipality in Rio Grande do Sul, with 42 network workers. For data collection, participant observation, semi-structured interviews and open forum were used. For data analysis, thematic analysis was used. Results: the network’s mission involved a proposal for care without prejudice and judgments for drug users. It was identified that the composition of the network with training in multidisciplinary residency and psychiatry facilitates achieving the mission, and among the difficulties, the challenges to overcome prejudice were analyzed. Strategies for continuing education, seminars, and user empowerment in the community are suggested. Final considerations: stigma and prejudice need to be problematized in the networks for the organization of more inclusive and rehabilitating psychosocial care.

show abstract

Section: Discussionmentioning

confidence: 91%

Assessment of stigma and prejudice in the organization of care networks for drug users

et al. 2022

View full text Add to dashboard Cite

show abstract

“…As such, the population with OUD and StUD is growing, and the health and substance use service needs of this population require increased attention. This may necessitate ongoing education for care providers [40], given people who use stimulants such as methamphetamine have been known to face stigma in their health care encounters [41][42][43] which can be compounded by concurrent mental illness [44].…”

Section: Discussionmentioning

confidence: 99%

Stimulant use disorder diagnosis and opioid agonist treatment dispensation following release from prison: a cohort study

Palis

Zhao²,

Young³

et al. 2022

Subst Abuse Treat Prev Policy

View full text Add to dashboard Cite

Background Concurrent opioid and stimulant use is on the rise in North America. This increasing trend of use has been observed in the general population, and among people released from prison in British Columbia (BC), who face an elevated risk of overdose post-release. Opioid agonist treatment is an effective treatment for opioid use disorder and reduces risk of overdose mortality. In the context of rising concurrent stimulant use among people with opioid use disorder, this study aims to investigate the impact of stimulant use disorder on opioid agonist treatment dispensation following release from prison in BC. Methods Linked health and corrections records were retrieved for releases between January 1st 2015 and December 29th 2018 (N = 13,380). Hospital and primary-care administrative health records were used to identify opioid and stimulant use disorder and mental illness. Age, sex, and health region were derived from BC’s Client Roster. Incarceration data were retrieved from provincial prison records. Opioid agonist treatment data was retrieved from BC’s provincial drug dispensation database. A generalized estimating equation produced estimates for the relationship of stimulant use disorder and opioid agonist treatment dispensation within two days post-release. Results Cases of release among people with an opioid use disorder were identified (N = 13,380). Approximately 25% (N = 3,328) of releases ended in opioid agonist treatment dispensation within two days post-release. A statistically significant interaction of stimulant use disorder and mental illness was identified. Stratified odds ratios (ORs) found that in the presence of mental illness, stimulant use disorder was associated with lower odds of obtaining OAT [(OR) = 0.73, 95% confidence interval (CI) = 0.64–0.84)] while in the absence of mental illness, this relationship did not hold [OR = 0.89, 95% CI = 0.70–1.13]. Conclusions People with mental illness and stimulant use disorder diagnoses have a lower odds of being dispensed agonist treatment post-release compared to people with mental illness alone. There is a critical need to scale up and adapt opioid agonist treatment and ancillary harm reduction, and treatment services to reach people released from prison who have concurrent stimulant use disorder and mental illness diagnoses.

show abstract

“…Other common barriers are lack of knowledge about the harmful effects of continued substance use, patients' belief that they can cope with substance use on their own or the problem will improve by itself, and embarrassment (Mowbray et al, 2010;Perron et al, 2009). Stigma is a significant barrier to accessing SUD treatment services; individuals may choose to conceal their substance use to avoid it (Livingston, Milne, Fang, & Amari, 2012;Woodhead, Timko, Han, & Cucciare, 2018).…”

Section: Patient Factorsmentioning

confidence: 99%

“…Provider factors that may influence patients' transitions to SUD specialty care include providers' cultural competence (Masson et al, 2013) and knowledge about the availability and potential efficacy of SUD treatment options both within their care system and larger community. Referrals to SUD treatment may be infrequent because providers often view such treatment as a revolving door that does not deliver positive outcomes (Woodhead et al, 2018).…”

Section: Provider Factorsmentioning

confidence: 99%

Foundations of Behavioral Health

Hanson¹

2020

View full text Add to dashboard Cite

show abstract

Stigma, treatment, and health among stimulant users: Life stage as a moderator

Cited by 8 publications

References 69 publications

Assessment of stigma and prejudice in the organization of care networks for drug users

Assessment of stigma and prejudice in the organization of care networks for drug users

Stimulant use disorder diagnosis and opioid agonist treatment dispensation following release from prison: a cohort study

Foundations of Behavioral Health

Contact Info

Product

Resources

About